Soluble urokinase receptor levels are correlated with focal segmental glomerulosclerosis lesions in IgA nephropathy: A cohort study from China

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Guo, Shui Ming ^a   Han, Min ^a   Chen, Mei Xue ^a   Ning, Yong ^a   Pei, Guang Chang ^a   Li, Yue Qiang ^a   Dai, Wei ^a   Ge, Shu Wang ^a   Deng, Yuan Jun ^a   Guo, Yan Yan ^a   Li, Xiao Qing ^a   Haller, Hermann ^b   Xu, Gang ^a   Rong, Song ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; SOLUBLE UROKINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADULT; AGE; ARTICLE; BLOOD LEVEL; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOCAL GLOMERULONEPHRITIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; YOUNG ADULT; ADOLESCENT; BLOOD; FOCAL GLOMERULOSCLEROSIS; KIDNEY; KIDNEY FUNCTION TEST; PATHOLOGY; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; CHINA; COHORT STUDIES; FEMALE; GLOMERULONEPHRITIS, IGA; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84946576797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138718     Document Type: Article

References (37)

1. Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5): 534-45. doi: 10.1038/ki.2009.243 PMID: 19571791
2. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990; 89(2): 209-15. PMID: 2200265
3. Working Group of the International Ig ANN, the Renal Pathology S, Roberts IS, Cook HT, Troyanov S, Alpers CE, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5): 546-56. doi: 10.1038/ki.2009.168 PMID: 19571790
4. DAmico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000; 36(2): 227-37. doi: 10.1053/ajkd.2000.8966 PMID: 10922300
5. Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol Dial Transplant. 2002; 17(1): 64-9. PMID: 11773464
6. Donadio JV, Grande JP. IgA nephropathy. N EnglJ Med. 2002; 347(10): 738-48. doi: 10.1056/NEJMra020109 PMID: 12213946
7. A multicenter study of IgA nephropathy in children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int. 1982; 22(6): 643-52. PMID: 6761487
8. Sinniah R. Idiopathic IgA mesangial nephropathy: histological features. Contrib Nephrol. 1984; 40: 156-66. PMID: 6388996
9. Haas M. Histologic subclassification of IgA nephropathy: aclinicopathologicstudy of 244 cases. Am J Kidney Dis. 1997; 29(6): 829-42. PMID: 9186068
10. Hill GS, Karoui KE, Karras A, Mandet C, Duong Van Huyen JP, Nochy D, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int. 2011; 79(6): 635-42. doi: 10.1038/ki.2010.466 PMID: 21160460
11. El Karoui K, Hill GS, Karras A, Moulonguet L, Caudwell V, Loupy A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int. 2011; 79(6): 643-54. doi: 10.1038/ki.2010.460 PMID: 21178978
12. Weber CL, Rose CL, Magil AB. Focal segmental glomerulosclerosis in mild IgA nephropathy: a clinical-pathologic study. Nephrol Dial Transplant. 2009; 24(2): 483-8. doi: 10.1093/ndt/gfn513 PMID: 18786972
13. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptorasa cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17(8): 952-60. doi: 10.1038/nm.2411 PMID: 21804539
14. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012; 23(12): 2051-9. doi: 10.1681/ASN.2012030302 PMID: 23138488
15. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int. 2013; 84(2): 366-72. doi: 10.1038/ki.2013.55 PMID: 23447064
16. Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014; 85(3): 636-40. doi: 10.1038/ki.2013.505 PMID: 24402090
17. Qin DD, Song D, Huang J, Yu F, Zhao MH. Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China. Lupus. 2014. doi: 10.1177/0961203314558857 PMID: 25411257
18. Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int. 2014; 85(3): 641-8. doi: 10.1038/ki.2013.544 PMID: 24429394
19. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3(12): 932-43. doi: 10.1038/nrm977 PMID: 12461559
20. Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation. 2013; 96(4): 394-9. doi: 10.1097/TP.0b013e3182977ab1 PMID: 23736353
21. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014; 12: 81. doi: 10.1186/1741-7015-12-81 PMID: 24884842
22. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86 (4): 828-36. doi: 10.1038/ki.2014.63 PMID: 24694989
23. Zeng CH, Le W, Ni Z, Zhang M, Miao L, Luo P, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis. 2012; 60(5): 812-20. doi: 10.1053/j.ajkd.2012.06.011 PMID: 22819700
24. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011; 80(3): 310-7. doi: 10.1038/ki.2011.126 PMID:21544062
25. Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol. 2011; 6(9): 2175-84. doi: 10.2215/CJN.11521210 PMID: 21852672
26. Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2012; 27(1): 252-8. doi: 10. 1093/ndt/gfr295 PMID: 21606384
27. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schonlein nephritis. Nat Rev Nephrol. 2013; 9(6): 320-7. doi: 10.1038/nrneph.2013.59 PMID: 23545591
28. Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, et al. A reassessment of soluble uro-kinase-type plasminogen activator receptor in glomerular disease. Kidney Int. 2015; 87(3): 564-74. doi: 10.1038/ki.2014.346 PMID: 25354239
29. Deegens JK, Wetzels JF. Glomerular disease: The search goes on: suPARis not the elusive FSGS factor. Nat Rev Nephrol. 2014; 10(8): 431-2. doi: 10.1038/nrneph.2014.113 PMID: 24957131
30. Maas RJ, Wetzels JF, Deegens JK. Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease. Kidney Int. 2014; 85(3): 711. doi: 10.1038/ki.2013.513 PMID: 24583989
31. Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int. 2015; 87(1): 210-6. doi: 10.1038/ki.2014.197 PMID: 24897037
32. Theilade S, Lyngbaek S, Hansen TW, Eugen-Olsen J, Fenger M, Rossing P, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med. 2015; 277(3): 362-71. doi: 10.1111/joim.12269 PMID: 24830873
33. Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015; 26(1): 133-47. doi: 10.1681/ASN.2013111213 PMID: 24925721
34. Ye ZC, Wang C, Tang Y, Liu X, Peng H, Zhang H, et al. Serum IgA1 from patients with IgA nephropathy up-regulates integrin-linked kinase synthesis and inhibits adhesive capacity in podocytes through indirect pathways. Clin Invest Med. 2009; 32(1): E20-7. PMID: 19178875
35. Coppo R, Fonsato V, Balegno S, Ricotti E, Loiacono E, Camilla R, et al. Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int. 2010; 77(5): 417-27. doi: 10.1038/ki.2009.473 PMID: 20016469
36. Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Lai FM, et al. Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol. 2008; 294(4): F945-55. doi: 10.1152/ajprenal.00423.2007 PMID: 18256312
37. Shushakova N, Tkachuk N, Dangers M, Tkachuk S, Park JK, Hashimoto K, et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci. 2005; 118(Pt 12): 2743-53. doi: 10. 1242/jcs.02409 PMID: 15944400